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Aims. Diabetic cardiomyopathy, characterized by left ventricular (LV) dysfunction and hyper-
trophy (LVH) independent of myocardial ischemia and hypertension could contribute to the in-
creased life-time risk of congestive heart failure seen in patients with diabetes. We assessed 
prospectively prevalence, screening methods (brain natriuretic peptide (BNP) and CRP in 
combination with clinical parameters) and outcome of preclinical diabetic cardiomyopathy. 
Methods and results. We studied 100 adults (mean age 57.4±10.2 years, 44% females) with 
diabetes and no previous evidence of structural heart disease. By echocardiography, diabetic 
cardiomyopathy was present in 48% of patients. Screening with combinations of clinical para-
meters (gender, systolic blood pressure and body mass index), but not BNP, resulted in high 
negative predictive values for diabetic cardiomyopathy. During a mean follow-up of 48.5±9.0 
months 12.5% vs 3.9% (p<0.2) experienced death or cardiovascular events and 37.5% versus 
9.6% (p<0.002) a deterioration of NYHA functional class with an overall event-free survival 
of 54 versus 87% (p=0.001) in the groups with and without diabetic cardiomyopathy. BNP 
was an independent predictor of events (OR 3.5 (1.1-10.9), p=0.02). 
Conclusions. Preclinical diabetic cardiomyopathy is common. Screening with combinations of 
simple clinical parameters, but not BNP, can be useful to identify those patients needing further 
evaluation. Patients with preclinical diabetic cardiomyopathy are at increased risk for 
functional deterioration and possibly cardiovascular events during follow-up. BNP was shown 
to be an independent predictor of future events. 
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Cardiovascular complications, mainly as a consequence of premature and accelerated co-
ronary disease, are the leading cause of morbidity and mortality in patients with diabetes (1). In 
addition, there is an increased life-time risk of congestive heart failure and these patients are 
over-represented in large heart failure databases (2). Clinical and experimental studies have 
supported the concept of a diabetic cardiomyopathy with functional, biochemical and mor-
phological myocardial abnormalities independent of myocardial ischemia and hypertension (3) 
leading to left ventricular (LV) dysfunction and hypertrophy (LVH) in a substantial proportion 
of type I and II diabetics (4-5). Still, only limited information is available regarding the 
prevalence and outcome of preclinical diabetic cardiomyopathy. 
Besides coronary disease, LV dysfunction and LVH are the most promising therapeutic 
targets to reduce cardiac morbidity and mortality in diabetic patients. Echocardiography, the 
cornerstone of diagnostic evaluation for LV dysfunction and LVH, is currently not performed 
routinely in diabetic patients because of limited availability and relatively high cost. Therefore, 
a simple test to detect those patients with the highest likelihood of LV dysfunction and LVH 
requiring further evaluation would be attractive. Brain natriuretic peptide (BNP) and high 
sensitivity c-reactive protein (hs-CRP) reflecting hemodynamic stress and inflammation, 
respectively, are potential biochemical screening tests for this purpose (6-10).  
Thus, the objectives of this pilot study in diabetic patients without previously known 
heart disease were: first, to assess the prevalence of systolic and diastolic LV dysfunction and 
LVH as diagnosed by comprehensive Doppler-echocardiography; second, to evaluate the 
usefulness of BNP and hs-CRP alone or in combination with clinical parameters as screening 






The investigation conforms with the principles outlined in the Declaration of Helsinki, 
the research protocol was approved by the local Ethics Committee and written informed con-
sent was obtained by all patients prior to inclusion in the study. 
 
Patients. We recruited prospectively from our diabetes outpatient clinic 100 adults with type I 
or II diabetes treated with insulin and/or oral antidiabetics who were in sinus rhythm. Exclu-
sion criteria included: previous diagnosis, symptoms or signs of heart failure, coronary or other 
structural heart disease; untreated hypertension; acute infections; alcohol or drug abuse and 
elevated serum creatinine. After a detailed history and physical examination including the 
Framingham heart failure criteria (11), nonfasting venous blood samples were obtained, a 
standard 12-lead ECG was acquired and a Doppler-echocardiography was performed on the 
same day.  
 
Laboratory analysis. Plasma BNP concentrations were measured with the Biosite® Access 
BNP-immunoassay and hs-CRP was determined by immunonephelometry on the Beckman 
Image Nephelometer. The detection limits are 5 pg/ml for BNP and 0.06 mg/l for hs-CRP, res-
pectively. In addition, serum creatinine, glucose, hemoglobin A1c, total cholesterol, LDL-chol-
esterol and triglycerides were measured by standard techniques.  
 
Echocardiography. Doppler-echocardiography was performed by one of two cardiologists 
(SK, PR) blinded to laboratory results using a Sonos 5500 system (Philips, Eindhoven, the Ne-
therlands).  
Two-dimensional echocardiography and M-mode measurements were obtained in stan-
dard fashion. LV ejection fraction was measured using a modified Simpson's rule algorithm or, 
if volumes could not be quantified due to limited image quality, by visual assessment. LV mass 
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was determined using Devereux's formula (12). Each participant underwent pulsed-wave 
Doppler examination of mitral and pulmonary venous inflow and Doppler tissue imaging of the 
mitral anulus. Peak values of mitral E- and A-wave velocities and E/A ratios before and during 
Valsalva maneuver, A-wave duration (Adur) and deceleration time of the E-wave (DT) were 
recorded and ∆E/A was calculated as E/A before – E/A during Valsalva maneuver. Pulmonary 
venous flow measurements included peak systolic (S) and diastolic (D) flow velocities and 
duration of atrial reversal flow (ARdur). In addition, tissue Doppler imaging of the mitral 
anulus was obtained in the apical four-chamber view and the early diastolic peak velocity (E’) 
was recorded. Mean heart rate during the Doppler study was 75±11 beats / minute. 
LV systolic dysfunction was defined as LV ejection fraction of <45 %  and LV end-
diastolic internal dimension index of >3.2 cm/m
2
 or LV end-diastolic volume index of >102 
ml/m
2 
(13). Diastolic dysfunction was categorized as mild, defined as impaired relaxation 
without evidence of increased filling pressures (E/A≤0.75, ∆E/A<0.5, E/e’<10, S>D, ARdur 
<Adur); moderate, defined as impaired relaxation associated with moderate elevation of filling 
pressures or pseudonormal filling (E/A>0.75-<1.50, DT>140 ms, ∆E/A≥0.5, E/e’≥10, S<D or 
ARdur>Adur+30ms); and severe, defined as advanced reduction in compliance or restrictive 
filling (E/A>1.5, DT<140ms, ∆E/A≥0.5 (reversible) or <0.5 (fixed), E/e’≥10, S<D or 
ARdur>Adur+30ms), as previously described (14). Participants with E/A>0.75 were required 
to have ≥2 additional Doppler criteria consistent with moderate or severe diastolic dysfunction 
to be so classified and were otherwise classified as indeterminate diastolic function. For further 
comparison, the groups with normal and indeterminate function were combined. LVH was de-
fined as LV mass index ≥131 g/m2 for men and ≥100 g/m2 for women (12).  
 
ECG. Electrocardiographic LVH was diagnosed with the Sokolow-Lyons index (SV1 + RV5-6) 
>38 mm or the Cornell modified index ((RaVL + SV3) x QRS duration in men; (RaVL + SV3  
+ 6 mm) x QRS duration in women)) > 2440 mm x ms (15). 
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Definition of preclinical diabetic cardiomypathy. Presence of left ventricular dysfunction 
and / or LVH by Doppler-echocardiography in type I or II diabetics treated with insulin and / 
or oral antidiabetics in the absence of clinical evidence of coronary / other structural heart di-
sease or untreated hypertension. 
 
Outcome. Patients were followed every 6 months for a minimum of 3 years by structured tele-
phone interview using a self-designed flow-sheet with the events in question defined according 
to standard clinical criteria. Medical records were reviewed in case of hospitalisation and 
referring physicians were contacted for additional information. Besides NYHA functional class 
(limitations of functional capacity due to shortness of breath as compared to the previous 
observation period) the following events were recorded: death (cardiac/noncardiac), acute 
coronary syndrome, hospitalisation for cardiac reasons and new diagnosis of heart failure. The 
physicians collecting the follow-up data (SK, RG, PR) were blinded to laboratory and 
echocardiographic results. 
 
Statistical analysis. Values are expressed as mean ±1 SD, median (IQR), or frequencies as in-
dicated. Between-group differences were compared using the chi-square test, Fisher’s exact 
test, or Student’s t-test, as appropriate. Because BNP and hs-CRP values were not normally 
distributed, the Mann-Whitney test was used for comparison. Receiver-operator-characteristic 
(ROC) curves were constructed to calculate the predictive values of BNP and hs-CRP for the 
diagnosis of LV dysfunction, LVH and diabetic cardiomyopathy and the values with best 
diagnostic accuracies where obtained. A multiple logistic regression model was used for eva-
luating the ability of biochemical markers to identify LV dysfunction, LVH and diabetic cardio-
myopathy over and above the information provided by other indicators. Sensitivity, specificity, 
positive (PPV) and negative (NPV) predictive values were calculated for independent 
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predictors. The effect of diabetic cardiomyopathy on outcome defined as events (see above), 
deterioraton of NYHA functional class and both these outcomes combined, was analyzed with 
the Kaplan-Meier method using log rank (Mantel-Cox) test to assess for equality of survival 
curves. Logistic regression was employed to calculate relative risks (95% CI) for selected out-
come variables with sufficient numbers of events and to evaluate the ability of BNP, clinical 
and echocardiogaphic parameters to predict prognosis. Statistical analyses were performed 
using commercially available software (Statview version 5.0, SAS Institute Inc., Cary, North 
Carolina and SPSS version 12.0, SPSS Inc., Chicago, Illinois). A p-value of <0.05 was 




Prevalence. Baseline characteristics of the total study population and the groups with and 
without diastolic dysfunction, LVH and diabetic cardiomyopathy are shown in Table 1. Diasto-
lic function was normal in 42 (42%), abnormal in 38 (38%) and indeterminate in the remaining 
20 (20%) patients. In those with abnormal diastolic function, severity was classified as mild in 
27 (71%), moderate in 10 (26%) and severe in 1 (3%) patients. LVH was diagnosed in 24 
patients (24%). No patient showed systolic dysfunction, the mean LV ejection fraction was 
62±6%. Forty-eight patients (48%) had diabetic cardiomyopathy. 
 
Screening. Median (IQR) BNP values in patients with normal, indeterminate and abnormal 
diastolic function were 21 (18), 30 (39) and 44 (58) pg/ml respectively (p=0.0003 between 
normal and abnormal function). Patients with mild, moderate and severe diastolic dysfunction 
showed median BNP values of 36 (55), 57 (60) and 167 pg/ml respectively (p=0.01 normal 
diastolic function vs mild and p=0.0011 normal vs moderate dysfunction). There was also a 
significant difference in median BNP values between patients with and without LVH (37 (54) 
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vs 29 (30) pg/ml; p<0.05) and in those with versus without diabetic cardiomyopathy (37 (50) 
vs 24 (22) pg/ml, p=0.0033). Values of hs-CRP were not significantly different in all those 
subgroups (data not shown). 
 The areas under the curve for the ROC analyses with BNP used to detect diastolic dys-
function, LVH and diabetic cardiomyopathy were 0.70 (0.59-0.81, p=0.001), 0.63 (0.51-0.76, 
p<0.05) and 0.67 (0.57-0.78, p=0.003) respectively. A BNP cutoff value of 34 pg/ml had a 
sensitivity of 66%, 58% and 58%, a specificity of 71%, 62% and 71%, a PPV of 58%, 33% 
and 65% and a NPV of 77%, 83% and 65% to detect any diastolic dysfunction, LVH and 
diabetic cardiomyopathy.  
 By multivariate logistic regression BNP, hypertension, systolic blood pressure were inde-
pendent predictors of diastolic dysfunction and female gender, systolic blood pressure, body 
mass index (BMI) of diabetic cardiomyopathy, respectively, whereas female gender remained 
as only independent predictor of LVH (data not shown). Sensitivities, specificities, NPV and 
PPV of the independent variables alone or in combination are shown in Table 2 and the clinical 
implications for screening based on these results in Table 3. BNP alone was only moderately 
useful to detect diastolic dysfunction alone whereas combinations of the clinical parameters 
listed above resulted in high negative predictive values for diabetic cardiomyopathy.  
 
Outcome. During a mean follow-up of 48.5±9.0 months (≥36 months except for one patient 
who moved to another country after 24 months) the following events were observed in the 
groups with and without diabetic cardiomyopathy: noncardiac deaths 2 versus 1, acute corona-
ry syndrome 2 versus 1, hospitalisation for cardiac reasons 4 versus 1 and new diagnosis of 
heart failure 2 versus 0; the number of patients with events was not significantly different bet-
ween the groups (6 (12.5%) vs 2 (3.9%), p<0.2)). Significantly more patients with diabetic 
cardiomyopathy experienced a deterioration of NYHA functional class (18 (37.5%) versus 5 
(9.6%), p<0.002; OR 4.5 (1.7-12.3), p=0.0009). The combined event-free survival was 54 ver-
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sus 87% (OR 3.8 (1.6-8.9), p=0.001) in the groups with and without diabetic cardiomyopathy 
as shown in figure 1. In addition, by univariate analysis, events were more likely to occur in pa-
tients with higher BNP (p=0.006) and older age (p<0.05), functional deterioration with higher 
BMI (p<0.003) and female gender (p<0.002) and the combined endpoint with higher BNP 
(p<0.006) and hs-CRP (p<0.04), higher BMI (p<0.03) older age (p<0.03) as well as female 
gender (p=0.007). BNP remained an independent predictor of events (OR 3.5 (1.1-10.9), 
p=0.02), female gender (OR 3.6 (1.2-10.8), p<0.02) and diabetic cardiomyopathy (OR 3.7 
(1.1-11.0), p<0.03) of functional deterioration and diabetic cardiomypathy alone (OR 3.5 (1.1-




 This study demonstrates that echocardiographic evidence for diabetic cardiomyopathy is 
common, especially in women, even in diabetic patients without previously known heart di-
sease. Screening with combinations of simple clinical parameters, but not BNP alone, can be 
useful to identify those patients needing further evaluation. This is of clinical importance as 
patients with preclinical diabetic cardiomyopathy are at increased risk for functional deterio-
ration and possibly cardiovascular events during follow-up. BNP was shown to be an indepen-
dant predictor of future events. 
 
Definition of diabetic cardiomyopathy. As mentioned earlier, in a strict sense, diabetic car-
diomyopathy has been defined as left ventricular dysfunction and/or hypertrophy independent 
of coronary disease and hypertension. However, a number of variations of this definition have 
been used in clinical studies. In the present analysis, patients did not have a history or symp-
toms suggestive of coronary disease and therefore no stress testing or coronary angiography 
were performed in the context of the study. Synergy between diabetes and hypertension is a 
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very frequent coincidence and there is evidence that their effect on the heart are similar, 
independent and synergistic (16). We decided not to exclude patients with hypertension if they 
were treated for this condition to better reflect the typical clinical scenario.  
 
Prevalence of diabetic cardiomyopathy. Numerous previous studies, using mainly Doppler 
echocardiography, have attempted to determine diastolic function in subjects with diabetes. 
Differences in the patient populations studied and in the definition of diastolic dysfunction 
most likely accounted for the highly varying prevalences of 30-75% reported in the literature 
(17-24). In our clinically well characterized population without evidence of heart disease, 
diastolic dysfunction was observed in 38%. This prevalence is higher than in the general popu-
lation. Others, using the same (14) or a comparable (25) definition of diastolic dysfunction 
found a prevalence of diastolic dysfunction in large community based populations of 27.4% 
and 29.1%, respectively. However, mean age was substantially higher in both reports as com-
pared to our population and a history of coronary disease, a previous myocardial infarction, a 
reduced ejection fraction (14) and heart failure (25) were not exclusion criteria, making a di-
rect comparison with our results difficult.  
 The prevalence of LVH in the general population is mainly dependent on age and the 
presence of hypertension, varying from 6% to over 50% in several large series (26-28). 
Increased left ventricular mass and wall thickness have also consistently been documented in 
diabetics (4, 5, 29). In the present study 24% had echocardiographic LVH. A higher preva-
lence of 43% has been described in unselected older patients with diabetes using the same 
definition for LVH in the only other publication reporting prevalence (23).  
 Diastolic dysfunction and/or LVH, as structural and functional evidence for preclinical 
diabetic cardiomyopathy, were present in 48% of our population. Remarkably, the prevalence 
of this entity was strikingly high in women in our study. Heart failure with preserved ejection 
fraction is commonly believed to be more common in women than in men but data regarding 
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gender differences in diabetic cardiomyopathy are rare in the literature. Only in the Framing-
ham study (5), an independant association was reported between diabetes and left ventricular 
mass in women only. Clearly, this issue merits further evaluation. 
 
Screening for diabetic cardiomyopathy. BNP was reported to reliably predict diastolic dys-
function in diabetic patients with and without clinical indications for echocardiography but, un-
fortunately, only little clinical information was provided in this study (30). In contrast, in a 
number of large, community-based populations BNP proved to be a suboptimal screening test 
to detect preclinical LV dysfunction or LVH (6-8). In addition, BNP was not useful to predict 
LV dysfunction in asymptomatic patients with diabetes in two small reports (31-32). In accor-
dance with these results, BNP was moderately predictive for the presence of LV diastolic dys-
function but not for LVH or diabetic cardiomyopathy in the present analysis. The combination 
of clinical parameters, mainly characteristics of the metabolic syndrome, resulted in high 
negative predictive values for diastolic dysfunction and diabetic cardiomyopathy. A substantial 
proportion of the diabetic population would need an echocardiogram with this approach, 
around one third of these would be negative but very few patients with diabetic cardiomyopa-
thy would be missed. 
Elevated hs-CRP levels have been shown to be associated with LVH in patients with 
type 2 diabetes (9) and have been identified as markers of future heart failure in the Framing-
ham population (10). Hs-CRP alone or in combination with BNP or clinical parameters did not 
prove to be useful as a diagnostic or prognostic marker regarding diabetic cardiomyopathy in 
our study. 
 
Outcome of diabetic cardiomyopathy. Our finding that patients with preclinical diabetic 
cardiomyopathy are at increased risk for adverse outcome driven mainly by symptomatic dete-
rioration may be seen as not surprising in view of the well established prognostic role of LVH 
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(33) and diastolic dysfunction (14) regarding cardiovascular morbidity and all-cause mortality. 
However, to our knowledge, this has not been reported yet. We found an almost 4-fold 
increased risk in patients with evidence for preclinical diabetic cardiomyopathy, underscoring 
the need for proper diagnostics and appropriate treatment in this population. In accordance 
with a recent report (34), patients with increased BNP levels are at particular risk. The results 
presented in this study may help to identify these patients.  
 
Limitations: A number of limitations apply to this study. First, no power calculation to 
determine sample size was performed because prevalence and outcome of preclinical diabetic 
cardiomyopathy were unknown at the time the study was designed. It can therefore not be ex-
cluded that the study was underpowered to detect differences regarding hard clinical end-
points. Second, silent coronary artery disease may have been the cause for some of the follow-
up events in addition to the three cases of acute coronary syndrome. Third, since arterial 
hypertension and systolic blood pressure were independently associated with diastolic dys-
function, hypertensive heart disease may have contributed to the echocardiographic findings 
besides diabetic cardiomyopathy. However, this does not limit the clinical implications of our 
study. 
  
Conclusions. The prevalence of preclinical diabetic cardiomyopathy is high in diabetics with-
out known structural heart disease and is associated with adverse outcome. Screening of dia-
betics based on combinations of simple clinical parameters, such as systolic blood pressure, 
BMI and gender can be useful to select those patients needing further evaluation with 
echocardiography. BNP alone was not a powerful screening test for diabetic cardiomyopathy 
but was shown to be an independant predictor of future events. Whether the structural and 
functional abnormalities of preclinical diabetic cardiomyopathy can be reversed and the 
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Figure 1. Event-free survival (death, acute coronary syndrome, hospitalisation for cardiac 
reasons, new diagnosis of heart failure, ≥1 increase in NYHA functional class) in patients with 
and without diabetic cardiomyopathy. 
Table 1. Baseline characteristics  
 
Parameter Total po-  Diastolic function  LVH  diabetic cardiomyopathy 
 pulation  normal abnormal p-value  absent present p-value  absent present p-value 
 (n=100)  (n=62) (n=38)   (n=76) (n=24)   (n=52) (n=48)  




61.6±9.9 <0.02  53.9±9.6 61.2±9.4 0.0002 




71 <0.005  27 63 0.0005 
Typ II diabetes (%) 78  74 84   76 83   73 83  
Diabetes duration (years) 12.1±10.4  12.4±10.4 11.6±10.5   12.0±10.6 12.3±9.8   11.9±9.9 12.3±10.9  
Hemoglobin A1c (%) 7.4±0.9  7.4±0.9 7.3±0.9   7.3±0.9 7.5±0.9   7.5±1.0 7.2±0.9  
Hypertension
*
 (%) 58  45 79
 
0.0009  59 54   48 69 <0.05 
Systolic BP
†
 (mmHg) 134±19  130±16 141±21
 
<0.003  132±18 140±21   130±17 139±19 <0.03 
Diastolic BP (mmHg) 80±12  79±12 81±12   80±12 81±14   79±12 81±13  
Hyperlipidemia‡ (%) 79  73 89 <0.05  80 75   73 85  
Total cholesterol (mmol/l) 5.0±1.0  4.9±0.9 5.1±1.0   5.0±0.9 4.8±1.1   4.9±0.9 5.1±1.0  
LDL-cholesterol (mmol/l) 3.0±0.9  3.0±0.9 3.1±0.9   3.1±0.9 2.9±0.9   3.0±0.9 3.0±0.8  
Triglycerides (mmol/l) 2.5±1.4  2.4±1.5 2.7±1.4   2.5±1.5 2.7±1.3   2.3±1.5 2.8±1.4  
Current smoker (%) 33  36 29   37 21   39 27  
Family history
§
 (%) 20  21 18   20 21   17 23  
Table
NYHA class I/II (%) 85/15  89/11 79/21   88/12 75/25   88/12 81/19  
Body mass index 30.1±5.2  29.5±5.0 31.1±5.3   29.5±5.1
 
32.0±5.2 <0.04  28.7±4.9 31.6±5.1 <0.005 
Medication history              
   Aspirin (%) 28  26 32   24 42   23 33  
   ACE-I/ARB
||
 (%) 54  48 63   50 67   48 60  
   Betablocker (%) 15  10 24
 
  19 25   6 25 <0.02 
   Calcium antagonist (%) 12  5 24
 
<0.009  12 13   4 21 <0.02 
   Diuretic (%) 30  23 42 <0.05  30 30   27 33  
   Statin (%) 43  44 43   45 38   48 38  
   Insulin (%) 28  32 21   29 25   34 21  
   Oral antidiabetic (%) 32  29 37   33 29   31 33  
   Both (%) 40  39 42   38 46   35 46  
ECG LVH (%) 3  0 8   3 4   0 6  
 
*
History of or current treatment for arterial hypertension; 
†
blood pressure; ‡Statin treatment or total cholesterol >5 mmol/l or LDL-cholesterol >3 mmol/l; §family history of 
premature coronary artery disease; 
||
ACE-inhibitor/angiotensin receptor blocker. 
 Table 2. 
Sensitivity, specificity, PPV and NPV of selected parameters to identify diastolic dysfunction, 
LVH and diabetic cardiomyopathy 
Diastolic dysfunction 
Parameter Sensitivity Specificity PPV NPV 
1. Hypertension 79 55 52 81 
2. SBP
*
>134 mmHg 63 72 59 75 
3. BNP >34 pg/ml 66 71 58 77 
1.+2. 87 46 50 85 
1.+3. 100 39 50 100 
2.+3. 84 46 49 82 
1.+2.+3. 100 26 45 100 
     
LVH   
Parameter Sensitivity Specificity PPV NPV 
Female gender 71 64 39 88 
     
Diabetic cardiomyopathy  
Parameter Sensitivity Specificity PPV NPV 
1. Female gender 63 73 68 68 
2. SBP >134 mmHg 60 76 71 67 
3. 
†
BMI>30.1 65 65 63 67 
1.+2. 88 52 63 82 
1.+3. 88 48 61 81 




Systolic blood pressure, 
†
Body Mass Index. 
 Table 3.  
Identification of diastolic dysfunction, LVH and diabetic cardiomyopathy: implications for 
screening 
Diastolic dysfunction (prevalence 38%) 
Parameter % screened needing 
echo 
% echos that are 
negative 
% with disease 
missed 
1. Hypertension 58 28 18 
2. SBP
*
>134 mmHg 42 17 14 
3. BNP >34 pg/ml 43 18 13 
1.+2. 66 33 5 
1.+3. 76 38 0 
2.+3. 65 33 6 
1.+2.+3. 84 46 0 
    
Left ventricular hypertrophy (prevalence 24%) 
Parameter % screened needing 
echo 
% echos that are 
negative 
% with disease 
missed 
Female gender 44 27 7 
    
Diabetic cardiomyopathy (prevalence 48%) 
Parameter % screened needing 
echo 
% echos that are 
negative 
% with disease 
missed 
1. Female gender 44 14 18 
2. SBP
*
 >134 mmHg 42 12 19 
3. 
†
BMI>30.1 49 18 17 
Table 3
 1.+2. 67 25 6 
1.+3. 69 27 6 
2.+3. 74 28 3 
1.+2.+3. 85 37 1 
*
Systolic blood pressure, 
†





Click here to download high resolution image
Word count 
 
3258 
*Word Count
